Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C23H21NO4 |
| Molecular Weight | 375.4171 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(NC1=CC=C(C=C1)C(O)=O)C(=O)C2=CC=C(C=C2)C3=CC=CC=C3
InChI
InChIKey=BPOMPTVRBWXZBY-UHFFFAOYSA-N
InChI=1S/C23H21NO4/c1-2-28-22(24-20-14-12-19(13-15-20)23(26)27)21(25)18-10-8-17(9-11-18)16-6-4-3-5-7-16/h3-15,22,24H,2H2,1H3,(H,26,27)
Xenazoic acid, an antiviral agent, was introduced in the early 1960s. Xenazoic acid might be of value in reducing the severity of meals infection if given early enough. Its use was associated with hepatic toxicity, which resulted in its withdrawal from the market in at least two countries (Belgium and France) in 1965. WHO has no information to suggest that xenazoic acid remains commercially available.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14021836
Single daily dose of 500 mg
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C281
Created by
admin on Wed Apr 02 09:29:28 GMT 2025 , Edited by admin on Wed Apr 02 09:29:28 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
58991
Created by
admin on Wed Apr 02 09:29:28 GMT 2025 , Edited by admin on Wed Apr 02 09:29:28 GMT 2025
|
PRIMARY | |||
|
CHEMBL1909289
Created by
admin on Wed Apr 02 09:29:28 GMT 2025 , Edited by admin on Wed Apr 02 09:29:28 GMT 2025
|
PRIMARY | |||
|
DTXSID10862575
Created by
admin on Wed Apr 02 09:29:28 GMT 2025 , Edited by admin on Wed Apr 02 09:29:28 GMT 2025
|
PRIMARY | |||
|
1174-11-4
Created by
admin on Wed Apr 02 09:29:28 GMT 2025 , Edited by admin on Wed Apr 02 09:29:28 GMT 2025
|
PRIMARY | |||
|
C66662
Created by
admin on Wed Apr 02 09:29:28 GMT 2025 , Edited by admin on Wed Apr 02 09:29:28 GMT 2025
|
PRIMARY | |||
|
43842
Created by
admin on Wed Apr 02 09:29:28 GMT 2025 , Edited by admin on Wed Apr 02 09:29:28 GMT 2025
|
PRIMARY | |||
|
SUB00101MIG
Created by
admin on Wed Apr 02 09:29:28 GMT 2025 , Edited by admin on Wed Apr 02 09:29:28 GMT 2025
|
PRIMARY | |||
|
100000079353
Created by
admin on Wed Apr 02 09:29:28 GMT 2025 , Edited by admin on Wed Apr 02 09:29:28 GMT 2025
|
PRIMARY | |||
|
1019
Created by
admin on Wed Apr 02 09:29:28 GMT 2025 , Edited by admin on Wed Apr 02 09:29:28 GMT 2025
|
PRIMARY | |||
|
59182
Created by
admin on Wed Apr 02 09:29:28 GMT 2025 , Edited by admin on Wed Apr 02 09:29:28 GMT 2025
|
PRIMARY | |||
|
KDU8VH09O8
Created by
admin on Wed Apr 02 09:29:28 GMT 2025 , Edited by admin on Wed Apr 02 09:29:28 GMT 2025
|
PRIMARY | |||
|
239062
Created by
admin on Wed Apr 02 09:29:28 GMT 2025 , Edited by admin on Wed Apr 02 09:29:28 GMT 2025
|
PRIMARY | |||
|
m532
Created by
admin on Wed Apr 02 09:29:28 GMT 2025 , Edited by admin on Wed Apr 02 09:29:28 GMT 2025
|
PRIMARY | Merck Index |
ACTIVE MOIETY